参考文献/References:
[1] Zimethaum PJ. Dronedarone for atrial fibrillationan odyssey[J]. N Engl J Med, 2009,360(18):1811-1813.
[2] Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone:an emerging agent with rhythm and rate controlling effects[J]. J Cardiovasc Electrophysiol,2006,17(12):S17- S20.
[3] Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone(SR33589), a noniodinated benzofuran derivative, in the rabbit heart:comparison with amiodarone[J].Circulation,1999,100(22):2276-2281.
[4] Hodeige D, Heyndrickx JP, Chatelain P, et al. SR 33589,a new amiodarone-like antiarrhythmic agent:anti-adrenoceptor activity in anaesthetized and conscious dogs[J]. Eur J Pharmacol,1995,279(1):25-32.
[5] Toubou1 P, Brugada J,Capucci A,et al.Dronedarone for prevention of atrial fibrillation:a dose-ranging study[J].Eur Heart J,2003,24(16):1481-1487.
[6] Singh BN, Connolly SJ, Crijins HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter[J]. N Engl J Med,2007,357:987-999.
[7] Davy JM, Herold M, Hoglund C, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation(ERATO)study[J]. Am Heart J, 2008,156(3):527.e1-e9.
[8] le Heuzey JY,de Ferrari GM,Radzik D,et al.A short-term,randomized,double-blind,parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation:the DIONYSOS study[J].J Cardiovasc Electrophysiol,2010,21(6):597-605.
[9] Kober L,Torp Pedersen C,McMurray JJ,et al.Increased mortality after dronedarone therapy for severe heart failure[J].N Engl J Med,2008,358(25):2678-2687.
[10] Hohnloser SH, Connolly SJ, Crijns H, et al. Rationale and Design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter[J]. J Cardiovasc Electrophysiol,2008,19:69-73.
[11] 石伟,邵江,庞小华. 决奈达隆治疗心房颤动/心房扑动临床实验荟萃分析[J].中国药房,2010,21(30):2852-2854.
[12] Cormolly SJ,Carom AJ,Halperin JL,et al. Dronedarone in high-risk permanent atrial fibrillation[J].N Engl J Med,2011,365(24):2268-2276.
[13] Frommeyer G, Milberg P, Schulze Grotthoff J, et al. Dronedarone and digitalis: individually reduced post-repolarization refractoriness enhances life-threatening arrhythmias[J].Europace,2015,17(8):1300-1308.
[14] Hohnloser SH, Connolly SJ, Camm JA, et al. An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation[J]. Europace,2014,16(8):1117-1124.
[15] 郭宗文,王丹丹,王徐乐,等. 决奈达隆治疗心房颤动、心房扑动有效性与安全性的Meta分析[J]. 海南医学,2014,25(16):2458-2463.
[16] Lee EJ,Kim J. Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation[J]. J Clin Pharm Ther,2014,39(2):112-117.
[17] Sohns C,von Gruben V,Sossalla S,et al. Antiarrhythmic drug therapy for maintaining sinus rhythm early after pulmonary vein ablation in patients with symptomatic atrial fibrillation[J]. Cardiovasc Ther,2014,32(1):7-12.
[18] Chun KJ,Byeon K,Im SI,et al. Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion[J]. Clin Ther,2014,36(9):1169-1175.
[19] Pisters R, Hohnloser SH, Connolly SJ,et al.Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial[J]. Europace,2014,16(2):174-181.
[20] Mason RP, Jacob RF, Jacoby AM, et al. Dronedarone enhanced endothelial nitric oxide release and reduced nitroxidative stress and blood pressure in hypertensive rats[J]. Circulation,2012,126(21 Suppl):A15691.
[21] Reiffel JA, Camm AJ, Belardinelli L,et al. The HARMONY Trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation:mechanistic and therapeutic synergism[J]. Circ Arrhythm Electrophysiol,2015,8(5):1048-1056.
[22] Dorian P. Clinical pharmacology of dronedarone:implications for the therapy of atrial fibrillation[J]. J Cardiovasc Pharmacol Ther,2010,15( 4 Suppl):15S-18S.
[23] Oyetayo OO, Rogers CE, Hofmann PO. Dronedarone: a new antiarrhythmic agents[J]. Pharmacotherapy, 2010,30(9):904-915.
[24] Wolbrette D, GonzaleZ M, Samii S,et al. Dronedarone for the treatment of atrial fibrillation and atrial flutter:approval and efficacy[J]. Vasc Health Risk Manag,2010,6: 517-523.
[25] Clem JR, Farver DK, Fischer JR, et al. Dronedarone: a safety comparison to aminodarone[J]. Curr Drug Saf,2010,5(3):251-256.
[26] FDA Drug Safety Communication. Severe liver injury associated with the use of dronedarone(marketed as Muhaq)[EB/OL].(2011-01-14)
[2011-9-29]http:// www.fda.gov/ Drugs/ DrugSafety/ ucm 24001 1.htm1.
[27] Chong CR, Licari G, Westley I, et al. Dronedarone is a potent cardiac and hepatic CPT-1 inhibitor[J]. Circulation,2014,130(Suppl 2):A12150.
[28] Friberg L. Safety of dronedarone in routine clinical care[J]. J Am Coll Cardiol,2014,63(22):2376-2384.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(4):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(4):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(4):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(4):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[8]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(4):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[9]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(4):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[10]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(4):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]